Guanhao Biotech Co.,Ltd. (SHE:300238)

Market Cap	3.74B +16.7%
Revenue (ttm)	386.40M +1.5%
Net Income	19.64M -29.6%
EPS	0.07 -31.6%
Shares Out	265.16M
PE Ratio	195.59
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,115,290
Average Volume	5,176,360
Open	14.21
Previous Close	14.53
Day's Range	14.04 - 14.49
52-Week Range	13.02 - 19.98
Beta	0.29
RSI	39.90
Earnings Date	Apr 29, 2026

About Guanhao Biotech

Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products in China. It offers NormalGEN and GrandNeuro, both a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological dura, a spinal patch; Type B dura, a spinal patch; Sterile Bio Wound Membrane; Ario Mesh; Thoracic Surgery Repair Diaphragm; and Cympic Benvimod Cream for psoriasis. In addit...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 535
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300238

Financial Performance

In 2025, Guanhao Biotech's revenue was 387.75 million, an increase of 2.72% compared to the previous year's 377.48 million. Earnings were 24.35 million, a decrease of -11.20%.